On June 19, SAMHSA issued a notice of proposed rulemaking on the use of buprenorphine
products in SAMHSA-certified opioid treatment programs (OTPs). If adopted, the proposal
would remove the time in treatment dispensing requirements for buprenorphine products
used to treat patients in OTPs. The dispensing restrictions would remain in effect for
patients treated with methadone. The closing date for comments on this proposal is August 19, 2009.
Federal Register Notice
Call 1 (888) 460-6556 to speak with a counselor.
